Tobramycin

Please Wait

Applying Filters...

FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

36 API Suppliers, 14 USDMF, 7 CEP/COS, 2 JDMF, 13 KDMF, 7 NDC API, 12 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

29 Drugs in Development

29 Drugs in Development

FINISHED DOSAGE FORMULATIONS

222 FDF Dossiers, 37 FDA Orange Book, 124 Europe, 7 Canada, 10 Australia, 14 South Africa, 30 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INHALATION - 28MG, SOLUTION/DROPS;OPHTHALMIC - 0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, OINTMENT;OPHTHALMIC - 0.3%, SUSPENSION/DROPS;OPHTHALMIC - 0.1%;0.3%, OINTMENT;OPHTHALMIC - 0.1%;0.3%, SOLUTION;INHALATION - 300MG/5ML, SUSPENSION/DROPS;OPHTHALMIC - 0.05%;0.3%

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 Pharm-RX Chemical, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 6 Actylis, 1 BASF, 1 CD Formulation, 1 Curia, 3 Finar, 1 JJ Chemicals, 1 Microlex e.U, 1 Nippon Fine Chemical, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

10 Parenteral, 5 Solubilizers, 5 Thickeners and Stabilizers, 3 Topical, 2 Film Formers & Plasticizers, 2 Emulsifying Agents, 1 Fillers, Diluents & Binders, 1 Rheology Modifiers, 1 Surfactant & Foaming Agents, 1 API Stability Enhancers, 1 Dry Powder Inhalation, 1 Controlled & Modified Release

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 38 News #PharmaBuzz

GLOBAL SALES INFORMATION

30 US Medicaid Prescriptions, 26 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

36 APIs, 6 FDF Dossiers

PATENTS & EXCLUSIVITIES

5 US Patents, 1 US Exclusivities, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM, 2 USP, 3 Others

$ Xls

Filters

SOLUTION;INHALATION - 300MG/5ML

SUSPENSION/DROPS;OPHTHALMIC - 0.1%;0.3%

OINTMENT;OPHTHALMIC - 0.1%;0.3%

OINTMENT;OPHTHALMIC - 0.3%

SOLUTION/DROPS;OPHTHALMIC - 0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 28MG

SUSPENSION/DROPS;OPHTHALMIC - 0.05%;0.3%

X

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Tobramycin

Tobramycin

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

36 API Suppliers

14 USDMF

7 CEP/COS

2 JDMF

13 KDMF

7 NDC API

12 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

29 Drugs in Development

FINISHED DOSAGE FORMULATIONS

222 FDF Dossiers

37 FDA Orange Book

124 Europe

7 Canada

10 Australia

14 South Africa

30 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INHALATION - 28MG

SOLUTION/DROPS;OPHTHALMIC - 0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

OINTMENT;OPHTHALMIC - 0.3%

SUSPENSION/DROPS;OPHTHALMIC - 0.1%;0.3%

OINTMENT;OPHTHALMIC - 0.1%;0.3%

SOLUTION;INHALATION - 300MG/5ML

SUSPENSION/DROPS;OPHTHALMIC - 0.05%;0.3%

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

1 Pharm-RX Chemical

1 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

3 Kirsch Pharma

6 Actylis

1 BASF

1 CD Formulation

1 Curia

3 Finar

1 JJ Chemicals

1 Microlex e.U

1 Nippon Fine Chemical

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

10 Parenteral

5 Solubilizers

5 Thickeners and Stabilizers

3 Topical

2 Film Formers & Plasticizers

2 Emulsifying Agents

1 Fillers, Diluents & Binders

1 Rheology Modifiers

1 Surfactant & Foaming Agents

1 API Stability Enhancers

1 Dry Powder Inhalation

1 Controlled & Modified Release

DIGITAL CONTENT

2 Data Compilation #PharmaFlow

38 News #PharmaBuzz

GLOBAL SALES INFORMATION

30 US Medicaid Prescriptions

26 Regulatory FDF Prices

2 Annual Reports

MARKET PLACE

36 APIs

6 FDF Dossiers

PATENTS & EXCLUSIVITIES

5 US Patents

1 US Exclusivities

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 EDQM

2 USP

3 Others

Filters

SOLUTION/DROPS;OPHTHALMIC - 0.3% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons